<DOC>
	<DOCNO>NCT01117103</DOCNO>
	<brief_summary>This observational , prospective , multicentric study conduct cohort subject type 2 diabetes prescribe Glucophage XR therapy hospital clinic Hong Kong , Indonesia , Korea , Malaysia , Philippines Singapore . Glucophage XR use Asia Pacific region treatment subject type 2 diabetes . This study design provide information day to-day experience use Glucophage XR management subject type 2 diabetes use routine clinical practice Asia Pacific region .</brief_summary>
	<brief_title>A Prospective , Observational Study Assess Evaluate Use Glucophage XR Therapy Management Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Glucophage ( metformin ) standard first line therapy subject type 2 diabetes mellitus ( DM ) . The consensus statement American Diabetes Association European Association Study Diabetes recommend metformin therapy concurrent lifestyle intervention diagnosis . It well accept subject ' compliance therapy tend decrease dosage frequency increase hence regimen simplify far possible support good compliance therapy . The use extend release formulation metformin ( Glucophage XR ) support simplification treatment subject type 2 diabetes allow daily administration metformin . OBJECTIVES Primary objective : - To assess tolerability Glucophage XR therapy use routine clinical practice subject type 2 diabetes Secondary objective : - To assess effectiveness Glucophage XR therapy maintenance glycaemic control The study involve active involvement subject require change standard medical management subject . Each subject follow upon start Glucophage XR therapy least 12 week treatment discontinuation treatment , whichever early .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes Subjects give Glucophage XR treatment type 2 diabetes Subjects treat Glucophage XR study initiation Contraindicated use Glucophage XR base local label Subjects plan continue another oral anti diabetic therapy course study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Glucophage</keyword>
	<keyword>Metformin</keyword>
</DOC>